BiotechTube

valacyclovir

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infectious Mononucleosis

Conditions

Infectious Mononucleosis

Trial Timeline

Feb 1, 2004 → Sep 1, 2005

NCT ID
NCT00274404

About valacyclovir

valacyclovir is a phase 1/2 stage product being developed by Roche for Infectious Mononucleosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00274404. Target conditions include Infectious Mononucleosis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT00274404Phase 1/2Completed

Competing Products

20 competing products in Infectious Mononucleosis

See all competitors
ProductCompanyStageHype Score
levofloxacinJohnson & JohnsonPhase 2/3
65
LevofloxacinJohnson & JohnsonPhase 3
77
AdalimumabAbbVieApproved
85
Acalabrutinib + RabeprazoleAstraZenecaPhase 1
33
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + TazobactamMerckPhase 2
52
Daptomycin + Standard of Care (SOC)MerckApproved
85
MK-7655 + Imipenem + Cilastatin + Caffeine + Midazolam + OmeprazoleMerckPhase 1
33
TR-701 200 mg + TR-701 300 mg + TR-701 400 mgMerckPhase 2
52
Tedizolid Phophate + Antibiotic comparator + Aztreonam + MetronidazoleMerckPhase 3
77
FTY720 + Oral CorticosteroidNovartisPhase 2
52
Daptomycin + Vancomycin + TeicoplaninNovartisPhase 3
77
PTK 0796 + linezolid + moxifloxacinNovartisPhase 3
77
LFG316 + Conventional TherapyNovartisPhase 2
52
AIN457 + PlaceboNovartisPhase 3
77
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77
AIN457 + AIN 457 + AIN457NovartisPhase 2
52
Filgotinib + Placebo to match filgotinib + PrednisoneGilead SciencesPhase 2
51
Tigecycline + vancomycin with aztreonamPfizerPhase 3
76
TigecyclinePfizerApproved
84
Avibactam sodium/Ceftazidime hydratePfizerPre-clinical
22

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85